• Intranet
    DARE-NL
    • About
      • DARE-NL
      • What are ATMPs (ENG)
      • More information
      • Wat zijn ATMPs (NL)
      • Meer weten?
    • Activities
      • Workpackage 1
      • Workpackage 2
      • Workpackage 3
      • Workpackage 4
      • Workpackage 5
      • Workpackage 6
      • Workpackage 7
    • People and Partners
      • Organisation
      • Supporting organisations
      • Management Team
      • Project Team
      • Steering Committee
      • Patient Advisory Board
      • Patient Participation Review Committee
      • Scientific Advisory Board
      • Vacancies
    • Courses & Events
      • Course directory
      • Submit new course
      • External course directories
      • Educational Programs
      • Upcoming events
      • Past events
      • Annual meeting
        • Annual meeting 2025
          • Program
          • Sponsors
          • Pictures
        • Annual Consortium Meeting 2024
        • Annual Consortium Meeting 2023
    • Resources
      • Tools
        • ATMP & Regenerative medicine
        • Regulations
        • Costs and lead times
        • Clinical trials
      • Publications
        • All publications
        • News items
        • Scientific articles
      • Newsletters
      • Links
    • Get in touch
    • Click to open the search input field Click to open the search input field Search
    • Menu Menu

    Information by the ZIN about the new European HTA legislation (in Dutch)

    News items
    https://www.dare-nl.nl/wp-content/uploads/2024/12/ZINbericht.png 632 769 Adel Medzikovic https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Adel Medzikovic2024-12-10 14:54:592025-02-03 10:42:46Information by the ZIN about the new European HTA legislation (in Dutch)

    Launch of new guidebook for ATMP developers by FAST

    News items
    https://www.dare-nl.nl/wp-content/uploads/2024/11/FASTartikel22nov.png 1248 2400 Adel Medzikovic https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Adel Medzikovic2024-11-21 13:34:392025-01-24 09:13:54Launch of new guidebook for ATMP developers by FAST

    Two new EMA documents on regulatory science

    News items
    https://www.dare-nl.nl/wp-content/uploads/2024/12/EMA_3.png 1044 1633 Adel Medzikovic https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Adel Medzikovic2024-11-14 17:15:032025-01-22 10:51:55Two new EMA documents on regulatory science

    Rapport Academie-gedreven geneesmiddelenontwikkeling door SiRM (in Dutch)

    News items
    https://www.dare-nl.nl/wp-content/uploads/2024/10/FASTartikel-22okt_2.png 667 581 Adel Medzikovic https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Adel Medzikovic2024-10-17 06:09:432024-12-17 17:21:33Rapport Academie-gedreven geneesmiddelenontwikkeling door SiRM (in Dutch)

    Behandeling van kanker in een vroeg stadium met innovatieve geneesmiddelen: wat is het ons waard? (in Dutch)

    News items
    https://www.dare-nl.nl/wp-content/uploads/2024/10/Interview_MSD_2.png 280 257 Adel Medzikovic https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Adel Medzikovic2024-10-08 12:10:482024-12-10 14:55:56Behandeling van kanker in een vroeg stadium met innovatieve geneesmiddelen: wat is het ons waard? (in Dutch)

    Pictures annual DARE-NL meeting 2024

    News items
    https://www.dare-nl.nl/wp-content/uploads/2024/09/image00004.jpeg 1555 2400 Adel Medzikovic https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Adel Medzikovic2024-10-01 10:19:372024-10-21 12:16:59Pictures annual DARE-NL meeting 2024

    Overzicht early access programma’s door Hollandbio (in Dutch)

    News items
    https://www.dare-nl.nl/wp-content/uploads/2024/10/Early-acces-Hollandbio_5.png 496 1006 Adel Medzikovic https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Adel Medzikovic2024-09-03 11:46:382024-11-22 13:35:46Overzicht early access programma’s door Hollandbio (in Dutch)

    The Value of Gene Therapy. A study of the growth, cost and accessibility of gene therapy products (in English and Dutch)

    News items
    https://www.dare-nl.nl/wp-content/uploads/2024/06/Knipsel.jpg 679 543 Simone Punt https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Simone Punt2024-06-25 08:03:432024-10-21 12:50:25The Value of Gene Therapy. A study of the growth, cost and accessibility of gene therapy products (in English and Dutch)

    Anke Hövels, KWF: Samen voor betere behandeling voor elke patiënt met kanker (in Dutch)

    News items
    https://www.dare-nl.nl/wp-content/uploads/2024/05/Knipsel-1.jpg 1017 951 Simone Punt https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Simone Punt2024-05-30 12:00:332024-10-01 10:20:19Anke Hövels, KWF: Samen voor betere behandeling voor elke patiënt met kanker (in Dutch)

    NTvH interview met Dr. Trudy Straetemans over DARE-NL (in Dutch)

    News items
    https://www.dare-nl.nl/wp-content/uploads/2024/05/NTvH-interview.png 900 1814 Simone Punt https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Simone Punt2024-05-08 12:00:012024-09-30 13:05:58NTvH interview met Dr. Trudy Straetemans over DARE-NL (in Dutch)
    Page 2 of 41234

    Contact us at info@dare-nl.nl

    Scroll to top Scroll to top Scroll to top
    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    • Manage options
    • Manage services
    • Manage {vendor_count} vendors
    • Read more about these purposes
    View preferences
    • {title}
    • {title}
    • {title}